## Alfonso Vignoli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10742806/publications.pdf

Version: 2024-02-01

623734 752698 20 1,228 14 20 citations g-index h-index papers 20 20 20 1390 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood, 2000, 96, 4261-4266.	1.4	259
2	Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Experimental Hematology, 2005, 33, 523-530.	0.4	212
3	Mechanisms and risk factors of thrombosis in cancer. Critical Reviews in Oncology/Hematology, 2017, 118, 79-83.	4.4	183
4	V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Experimental Hematology, 2007, 35, 702-711.	0.4	169
5	Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin. Thrombosis Research, 2008, 121, 637-645.	1.7	80
6	Clotting mechanisms and cancer: implications in thrombus formation and tumor progression. Clinical Advances in Hematology and Oncology, 2003, 1, 673-8.	0.3	75
7	Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms. Thrombosis and Haemostasis, 2010, 104, 151-156.	3.4	51
8	Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties. Haematologica, 2006, 91, 207-14.	3.5	31
9	Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study. Thrombosis Research, 2016, 140, S55-S59.	1.7	29
10	LMWH Bemiparin and ULMWH RO-14 Reduce the Endothelial Angiogenic Features Elicited by Leukemia, Lung Cancer, or Breast Cancer Cells. Cancer Investigation, 2011, 29, 153-161.	1.3	24
11	All-trans retinoic acid modulates microvascular endothelial cell hemostatic properties. Haematologica, 2003, 88, 895-905.	3.5	24
12	Thrombotic biomarkers for risk prediction of malignant disease recurrence in patients with early stage breast cancer. Haematologica, 2020, 105, 1704-1711.	3.5	21
13	Thrombin generation predicts early recurrence in breast cancer patients. Journal of Thrombosis and Haemostasis, 2020, 18, 2220-2231.	3.8	17
14	Comparative assessment of low-molecular-weight heparins in cancer from the perspective of patient outcomes and survival. Patient Related Outcome Measures, 2011, 2, 175.	1.2	15
15	Acute promyelocytic leukemia cell adhesion to vascular endothelium is reduced by heparins. Annals of Hematology, 2018, 97, 1555-1562.	1.8	13
16	Tissue Factor Expression on Platelet Surface during Preparation and Storage of Platelet Concentrates. Transfusion Medicine and Hemotherapy, 2013, 40, 126-132.	1.6	11
17	Bemiparin in Oncology. Drugs, 2010, 70, 35-42.	10.9	8
18	Heparins inhibit the endothelial pro-thrombotic features induced by tumor cells. Thrombosis Research, 2017, 157, 55-57.	1.7	4

## ALFONSO VIGNOLI

#	Article	IF	CITATIONS
19	Coagulation in Hematological Malignancies. Cancer Investigation, 2009, 27, 7-16.	1.3	1
20	Increased platelet thrombus formation under flow conditions in whole blood from polycythaemia vera patients. Blood Transfusion, $2021, \dots$	0.4	1